{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:17:36Z","timestamp":1789676256675,"version":"4.0.1"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":222,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2001,5,12]]},"abstract":"<jats:p><jats:bold>Summary:<\/jats:bold><jats:bold> \u2002Purpose: <\/jats:bold> To investigate the prevalence and prognosis of visual field defects (VFDs) in epilepsy patients with and without vigabatrin (VGB) treatment; to investigate the possible relationship between VFDs and cumulative VGB dose, and to characterise the evolution of VFDs.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A cohort of 155 presurgical candidates who had undergone full\u2010field Goldmann perimetry (GP) was studied, 99 (64%) of whom had been treated with VGB. All GPs were reevaluated in 1998 by one experienced examiner, blinded to medication. Duration of treatment and total VGB dose were related to perimetric results.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty\u2010five (16%) of the 155 patients had VFDs: Nineteen (19%) of the 99 VGB\u2010treated patients, and six (11%) of the 56 patients unexposed to VGB. VGB\u2010treated patients with VFDs had been treated significantly longer than those without VFDs. Cumulative VGB dose could be calculated for 84 patients. The prevalence of VFDs increased significantly with increasing total VGB\u2010dose, from 4% in the 51 patients who had been exposed to \u22641 kg VGB, to 75% in the eight patients with a total dose of 3\u20135 kg of VGB. Sixteen VGB\u2010treated patients were reexamined 2\u201310 years later. In the 12 where evaluation was possible, all still had VFDs, which had worsened in five cases (42%) and improved in none.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This study indicates a strong relationship between VFDs and duration and total dose of VGB. VFDs were irreversible and in a substantial percentage progressive. Similar VFDs may, however, also be found in patients unexposed to VGB. A model of the evolution of the VFDs in VGB toxicity is introduced, and a new simple visual field test is proposed.<\/jats:p>","DOI":"10.1046\/j.1528-1157.2001.28600.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T19:54:07Z","timestamp":1047412447000},"page":"609-615","source":"Crossref","is-referenced-by-count":93,"title":["Vigabatrin Visual Toxicity: Evolution and Dose Dependence"],"prefix":"10.1111","volume":"42","author":[{"given":"Kristina","family":"Malmgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Ben\u2010Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fris\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03466.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1981.tb00595.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03460.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/019262339001800201"},{"issue":"1","key":"e_1_2_5_6_2","first-page":"13","article-title":"Vigabatrin: effect on in vivo and ex vivo magnetic resonance imaging of dog brains [Abstract].","volume":"31","author":"Sussman NM","year":"1991","journal-title":"Epilepsia"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(94)90005-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(87)90054-4"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","unstructured":"Sivenius J Paljarvi L Vapalahti M et al.Vigabatrin (gamma\u2010vinyl\u2010GABA): neuropathologic evaluation in five patients.Epilepsia1993;34:193\u20136.","DOI":"10.1111\/j.1528-1157.1993.tb02398.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7075.180"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.614"},{"key":"e_1_2_5_12_2","first-page":"233","article-title":"Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin.","volume":"316","author":"Mackenzie R","year":"1998","journal-title":"BMJ"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.922"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.8.1713"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00212.x"},{"key":"e_1_2_5_16_2","first-page":"S565","article-title":"Visual field loss associated with vigabatrin.","volume":"40","author":"Zackon DH","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.67.6.716"},{"key":"e_1_2_5_18_2","first-page":"1","article-title":"The visual field in normal subjects.","volume":"169","author":"Egge K","year":"1984","journal-title":"Acta Ophthalmol"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1050110"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.1992.tb00952.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973477"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79254-0"},{"issue":"2","key":"e_1_2_5_23_2","first-page":"256","article-title":"Is visual impairment related to vigabatrin reversible?","volume":"40","author":"Arndt CF","year":"1999","journal-title":"Epilepsia"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.2082"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02569055"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb01599.x"},{"key":"e_1_2_5_27_2","volume-title":"Clinical tests of vision","author":"Fris\u00e9n L","year":"1990"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01203566","article-title":"High\u2010pass resolution perimetry: a clinical review.","volume":"83","author":"Fris\u00e9n L","year":"1996","journal-title":"Doc Ophthalmol"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1528-1157.2001.28600.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1528-1157.2001.28600.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T17:34:39Z","timestamp":1697650479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1528-1157.2001.28600.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5,12]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5,12]]}},"alternative-id":["10.1046\/j.1528-1157.2001.28600.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1528-1157.2001.28600.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5,12]]}}}